Show simple item record

dc.contributor.authorKhdour, Maher R.
dc.date.accessioned2020-07-21T11:24:55Z
dc.date.available2020-07-21T11:24:55Z
dc.date.issued2019-12-17
dc.identifier.issn2042-7158
dc.identifier.urihttps://dspace.alquds.edu/handle/20.500.12213/5715
dc.description.abstractAbstract Objectives This review surveys current pharmacotherapies available for the treatment of diabetic peripheral neuropathy (DPN), emphasising their mechanisms of action. Methods A comprehensive literature review focusing on the ‘pharmacotherapy and treatment of diabetic peripheral neuropathy’ was conducted. The Database of International Pharmaceutical Abstracts, EMBASE, PubMed, OVID, Scopus, Google and Google Scholar were searched, and reference lists of relevant articles were also included. Key findings Diabetic peripheral neuropathy is often inadequately treated, and the role of improving glycaemic control specifically in type-2 diabetes remains unclear. It is crucial to explore the mechanisms of action and effectiveness of available therapies. Major international clinical guidelines for the management of DPN recommend several symptomatic treatments. First-line therapies include tricyclic antidepressants, serotonin–noradrenaline reuptake inhibitors, and anticonvulsants that act on calcium channels. Other therapies include opioids and topical agents such as capsaicin and lidocaine. The objectives of this paper are to review current guidelines for the pharmacological management of DPN and to discuss research relevant to the further development of pharmacological recommendations for the treatment of diabetic neuropathy. Summary Diabetic neuropathy is a highly prevalent, disabling condition, the management of which is associated with significant costs. Evidence supports the use of specific anticonvulsants and antidepressants for pain management in patients with diabetic peripheral neuropathy. All current guidelines advise a personalised approach with a low-dose start that is tailored to the maximum response having the least side effects or adverse events.en_US
dc.language.isoenen_US
dc.publisherWiley-Blackwell on behalf of the Royal Pharmaceutical Society of Great Britainen_US
dc.subjectneuropathic painen_US
dc.subjectnoradrenaline reuptake inhibitorsen_US
dc.subjectopioidsen_US
dc.subjectpregabalinen_US
dc.subjecttricyclic antidepressantsen_US
dc.titleTreatment of diabetic peripheral neuropathy: a reviewen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record